Recents Post
Back-to-School Health: Helping Children Start the School Year Strong with Accordia Health
SARALAND, Ala., Aug. 26, 2026 /PRNewswire/ — As students return to school, parents are busy with supply lists, shopping for clothes, and getting ready for a great year. One of the best ways to help children succeed is…
Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
– ASP2138’s advancement into Phase 3 marks an important milestone in Astellas’ commitment to advancing research in CLDN18.2 with its differentiated portfolio, spanning approved treatments and investigational assets – TOKYO, Aug. 24, 2026 /PRNewswire/ — Astellas Pharma Inc. (TSE:…
Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion
TAIPEI, Aug. 23, 2026 /PRNewswire/ — Anbogen Therapeutics Inc. (TPEx: 7784) (“Anbogen” or the “Company”), a clinical-stage precision oncology company, today announced that it has entered into a Collaborative Research Agreement (CRA) with the Laboratory of Veterinary Surgery, Graduate…
NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
WASHINGTON, Aug. 22, 2026 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the NEREUS™ branded No. 47 entry from Rahal Letterman Lanigan Racing, driven by Mick Schumacher, is set to compete this weekend in the inaugural…
AbelZeta Regains Global Rights of C-CAR039 (Prizlon-cel) and Receives FDA Clearance of IND Application in Large B-cell Lymphoma
ROCKVILLE, Md. and SHANGHAI, Aug. 16, 2026 /PRNewswire/ — AbelZeta Pharma, Inc. (“AbelZeta” or the “Company”), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced that the…
Every enduring field of medicine is built on clinical architecture.
DAVIS, Calif., Aug. 5, 2026 /PRNewswire/ — Over decades, women’s healthcare organized itself around three foundational pillars: reproduction, disease prevention, and longevity. Those pillars shaped research, residency training, standards of care, and ultimately the questions physicians learned to…
Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China
SAN FRANCISCO and SUZHOU, China, Aug. 5, 2026 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and…
New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS
Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen listed on the Pharmaceutical Benefits Scheme (PBS) for adults with relapsed or refractory follicular lymphoma (R/R FL)…
ABOTA condemns targeting federal judges with social media threats
As threats to judicial independence continue to present, the legal profession must be proactive in defending against, condemning, and preventing unacceptable statements and conduct that pose a real and present danger to the third co-equal branch DALLAS, July 29,…
International Human Rights Attorney Zulu Ali Releases Groundbreaking New Book, Pan-African Justice, Introducing a New Legal Framework for Historical Harm and Human Rights
RIVERSIDE, Calif., July 27, 2026 /PRNewswire/ — International human rights attorney, trial lawyer, social entrepreneur and social commentator Zulu Ali, released the Kindle edition of his groundbreaking new book, Pan-African Justice: Historical Harm, Human Rights, and the Pursuit…
